RCT | Zolbetuximab plus mFOLFOX6 in CLDN18.2+ HER2- advanced gastric or gastro-oesophageal junction adenocarcinoma

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)

News Release: Results from Astellas’ Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet – PR Newswire